THERAPY FOR NON-INTENSIVE CARE UNIT HOSPITALIZED COVID-19 PATIENTS: RESULTS FROM A PILOT OPEN-LABEL, RANDOMIZED CONTROLLED CLINICAL TRIAL
M Z Haroon, U Farooq, S Ashraf, S Zeb, S Y Gillani, S Malik, R Ali, R Irshad, Z Mehmood, Y Abbas, A Masood, A Ghafoor, A T Khalil, H Asif, S Khan, I D Ujjan, R Nigar, S Livingstone, D A Pascual-Figal, S Togni, P Allegrini, A Riva, Dr Amjad Khan, Colchicine Anti-Inflammatory
doi:10.26402/jpp.2022.3.09
Systemic inflammation is a hallmark of severe coronavirus disease-19 . Anti-inflammatory therapy is considered crucial to modulate the hyperinflammatory response (cytokine storm) in hospitalized COVID-19 patients. There is currently no specific, conclusively proven, cost-efficient, and worldwide available anti-inflammatory therapy available to treat COVID-19 patients with cytokine storm. The present study aimed to investigate the treatment benefit of oral colchicine for hospitalized COVID-19 patients with suspected cytokine storm. Colchicine is an approved drug and possesses multiple anti-inflammatory mechanisms. This was a pilot, open-label randomized controlled clinical trial comparing standard of care (SOC) plus oral colchicine (colchicine arm) vs. SOC alone (control arm) in non-ICU hospitalized COVID-19 patients with suspected cytokine storm. Colchicine treatment was initiated within first 48 hours of admission delivered at 1.5 mg loading dose, followed by 0.5 mg b.i.d. for next 6 days and 0.5 mg q.d. for the second week. A total of 96 patients were randomly allocated to the colchicine (n=48) and control groups (n=48). Both colchicine and control group patients experienced similar clinical outcomes by day 14 of hospitalization. Treatment outcome by day 14 in colchicine vs control arm: recovered and discharged alive: 36 (75.0%) vs. 37 (77.1%), remain admitted after 14-days: 4 (8.3%) vs. 5 (10.4%), ICU transferred: 4 (8.3%) vs. 3 (6.3%), and mortality: 4 (8.3%) vs. 3 (6.3%). The speed of improvement of COVID-19 acute symptoms including shortness of breath, fever, cough, the need of supplementary oxygen, and oxygen saturation level, was almost identical in the two groups. Length of hospitalization was on average 1.5 day shorter in the colchicine group. There was no evidence for a difference between the two groups in the follow-up serum levels of inflammatory biomarkers including Creactive protein (CRP), D-dimer, lactate dehydrogenase (LDH), ferritin, interleukin-6 (IL-6), high-sensitivity troponin T (hs-TnT) and N-terminal pro b-type natriuretic peptide (NT pro-BNP). According to the results of our study, oral colchicine does not appear to show clinical benefits in non-ICU hospitalized COVID-19 patients with suspected cytokine storm. It is possible that the anti-inflammatory pathways of colchicine are not crucially involved in the pathogenesis of COVID-19. K e y w o r d s : COVID-19,
Conflict of interest: None declared.
References
Absalon-Aguilar, Rull-Gabayet, Perez-Fragoso, Colchicine is safe though ineffective in the treatment of severe COVID-19: a randomized clinical trial (COLCHIVID), J Gen Intern Med
Bernal, Da Silva, Musungaie, Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients, N Engl J Med
Cantini, Niccoli, Nannini, Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study, J Infect
Cecconi, Martinez-Vives, Vera, Efficacy of short-course colchicine treatment in hospitalized patients with moderate to severe COVID-19 pneumonia and hyperinflammation: a randomized clinical trial, Sci Rep,
doi:10.1038/s41598-022-13424-6Chalmers, Crichton, Goeminne, Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline, Eur Respir J,
doi:10.1183/13993003.00048-2021Cocco, Chu, Pandolfi, Colchicine in clinical medicine. A guide for internists, Eur J Intern Med
Core, A Language and Environment for Statistical Computing
Cummings, Baldwin, Abrams, Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study, Lancet
Da, Ae, Moral-Escudero, Colchicine in recently hospitalized patients with COVID-19: a randomized controlled trial (COL-COVID), Int J Gen Med
Deftereos, Giannopoulos, Vrachatis, Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: The GRECCO-19 Randomized Clinical Trial, JAMA Netw Open,
doi:10.1001/jamanetworkopen.2020.13136Diaz, Orlandini, Castellana, Effect of colchicine vs usual care alone on intubation and 28-day mortality in patients hospitalized with COVID-19: a randomized clinical trial, JAMA Netw Open,
doi:10.1001/jamanetworkopen.2021.41328Dorward, Russell, Um, Tissue-specific Immunopathology in fatal COVID-19, Am J Respir Crit Care Med
Dorward, Yu, Hayward, Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial, Br J Gen Pract
Dworakowska, Grossman, Renin-angiotensin system inhibitors in management of hypertension during the COVID-19 pandemic, J Physiol Pharmacol
Fajgenbaum, June, Cytokine storm, N Engl J Med
Fine, Gray, A proportional hazards model for the subdistribution of a competing risk, J Am Statist Assoc
Franchi, Warner, Viani, Nunez, Function of Nodlike receptors in microbial recognition and host defense, Immunol Rev
Gupta, Gonzalez-Rojas, Juarez, Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab, N Engl J Med
Henderson, Canna, Schulert, On the alert for cytokine storm: immunopathology in COVID-19, Arthritis Rheumatol
Herold, Jurinovic, Arnreich, Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19, J Allergy Clin Immunol
Huang, Pranata, Lim, Oehadian, Alisjahbana, C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis, Ther Adv Respir Dis,
doi:10.1177/1753466620937175Kalil, Patterson, Mehta, Baricitinib plus remdesivir for hospitalized adults with Covid-19, N Engl J Med
Koenker, Quantile Regression
Lazaros, Imazio, Brucato, The role of colchicine in pericardial syndromes, Curr Pharm Des
Leung, Hui, Kraus, Colchicine -update on mechanisms of action and therapeutic uses, Semin Arthritis Rheum
Leung, We also thank Roche and Health Ways Laboratories for helping in the biomarker's assays
Li, Meyerholz, Bartlett, Mccray, The TMPRSS2 inhibitor nafamostat reduces SARS-CoV-2 pulmonary infection in mouse models of COVID-19, mBio,
doi:10.1128/mBio.00970-21Li, Scheike, Zhang, Checking Fine and Gray subdistribution hazards model with cumulative sums of residuals, Lifetime Data Anal
Liu, Wang, Zhou, Zhao, Zhang et al., Potential role of ACE2 in coronavirus disease 2019 (COVID-19) prevention and management, J Transl Int Med
Lopes, Bonjorno, Giannini, Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial, RMD Open,
doi:10.1136/rmdopen-2020-001455Manji, Wang, Geddes, PYPAF1, a PYRINcontaining Apaf1-like protein that assembles with ASC and regulates activation of NF-kappa B, J Biol Chem
Martinon, Burns, Tschopp, The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta, Mol Cell
Marzolini, Kuritzkes, Marra, Recommendations for the management of drug-drug interactions between the COVID-19 antiviral Nirmatrelvir/Ritonavir (Paxlovid) and comedications, Clin Pharmacol Ther,
doi:10.1002/cpt.2646Moore, June, Cytokine release syndrome in severe COVID-19, Science
Owen, Allerton, Anderson, An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19, Science
Pourdowlat, Saghafi, Mozafari, Efficacy and safety of colchicine treatment in patients with COVID-19: a prospective, multicenter, randomized clinical trial, Phytother Res
Rabbani, Parikh, Rafique, Colchicine for the treatment of myocardial injury in patients with coronavirus disease 2019 (COVID-19) -an old drug with new life?, JAMA Netw Open,
doi:10.1001/jamanetworkopen.2020.13556Recovery Collaborative, Colchicine in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial, Lancet Respir Med
Rodrigues, De Sa, Ishimoto, Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients, J Exp Med,
doi:10.1084/jem.20201707Ruan, Yang, Wang, Jiang, Song, Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China, Intensive Care Med
Simsek-Yavuz, Celikyurt, An update of anti-viral treatment of COVID-19, Turk J Med Sci
Somersan-Karakaya, Mylonakis, Menon, Casirivimab and Imdevimab for the treatment of hospitalized patients with COVID-19, J Infect Dis,
doi:10.1093/infdis/jiac320Tardif, Bouabdallaoui, Allier, Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial, Lancet Respir Med
Yu, Qin, Chen, Wang, Tian, D-dimer level is associated with the severity of COVID-19, Thromb Res
Zawilska, Lagodzinski, Berezinska, COVID-19: from the structure and replication cycle of SARS-CoV-2 to its disease symptoms and treatment, J Physiol Pharmacol
DOI record:
{
"DOI": "10.26402/jpp.2022.3.09",
"URL": "https://doi.org/10.26402/jpp.2022.3.09",
"container-title": "Journal of Physiology and Pharmacology",
"issued": {
"date-parts": [
[
2022
]
]
},
"language": "eng",
"publisher": "Polish Physiological Society",
"publisher-place": "PL",
"title": "Colchicine anti-inflammatory therapy for non-intensive care unit hospitalized COVID-19 patients: results from a pilot open-label, randomized controlled clinical trial",
"type": "article-journal"
}
